EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
EQS-Ad-hoc: Fresenius SE Co. KGaA / Key word(s): Change in Forecast
Fresenius SE Co. KGaA: Fresenius raises outlook for fiscal year 2024
07-May-2024 / 21:19 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Fresenius SE Co. KGaA: Fresenius raises outlook for fiscal year 2024
Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024.
Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (previously: 3 to 6%). Group EBIT at constant currency is now expected to grow between 6 and 10% (previously: 4 to 8%).
The increase of the group outlook is based on improved business prospects for Fresenius Kabi. Fresenius Kabi now expects organic revenue growth in the mid to high single-digit percentage range for fiscal year 2024 (previously: mid single-digit percentage range). The EBIT margin is now expected to range between 15 and 16% (previously: around 15%).
The adjustment of the group outlook also reflects the fact that the forecast is now provided without Fresenius Vamed, i.e. exclusively for the operating companies Fresenius Kabi and Fresenius Helios. Following the announcement of the planned divestment of Fresenius Vamed’s rehabilitation business, Fresenius has initiated its structured exit from its investment company Fresenius Vamed.
For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.
Fresenius SE Co. KGaA,
represented by Fresenius Management SE,
The Management Board
Bad Homburg v.d.H., May 7, 2024
----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
----------------------------------------
End of Note
Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024.
Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (previously: 3 to 6%). Group EBIT at constant currency is now expected to grow between 6 and 10% (previously: 4 to 8%).
The increase of the group outlook is based on improved business prospects for Fresenius Kabi. Fresenius Kabi now expects organic revenue growth in the mid to high single-digit percentage range for fiscal year 2024 (previously: mid single-digit percentage range). The EBIT margin is now expected to range between 15 and 16% (previously: around 15%).
The adjustment of the group outlook also reflects the fact that the forecast is now provided without Fresenius Vamed, i.e. exclusively for the operating companies Fresenius Kabi and Fresenius Helios. Following the announcement of the planned divestment of Fresenius Vamed’s rehabilitation business, Fresenius has initiated its structured exit from its investment company Fresenius Vamed.
For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures.
Fresenius SE Co. KGaA,
represented by Fresenius Management SE,
The Management Board
Bad Homburg v.d.H., May 7, 2024
----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com
----------------------------------------
End of Note
End of Inside Information
07-May-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
End of Announcement EQS News Service
1898031 07-May-2024 CET/CEST